Skip to search formSkip to main contentSkip to account menu

Antibody-drug Conjugate ADCT-402

Known as: ADC ADCT-402, ADCT-402, Anti-CD19 PBD-conjugate ADCT-402 
An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6… 
2019
2019
refractory to prior therapy. CRS (according to the criteria by Lee et al. Blood 2014) occurred in 45 patients (23% G1, 24% G2, 3… 
2019
2019
A new investigational drug called ADCT-402 that combines a cell-killing compound with a monoclonal antibody shows early promise… 
2018
2018
Introduction: Diffuse large B-cell lymphoma (DLBCL) represents 33% of the non-Hodgkin lymphomas (NHL) and expresses CD19, a… 
2018
2018
Introduction: CD19, a B-cell surface antigen, is overexpressed in neoplastic lymphoid cells. ADCT-402 (loncastuximab tesirine… 
2017
2017
Introduction: Outcomes of patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remain dismal… 
2017
2017
Introduction : CD19 is expressed on the cell surface of many types of non-Hodgkin lymphoma (NHL), including follicular lymphoma… 
2016
2016
TPS7580Background: In normal human tissue, expression of cluster of differentiation 19 (CD19) is limited to the developmental… 
2015
2015
Human CD19 antigen is a 95 kilodalton type I transmembrane glycoprotein belonging to the immunoglobulin superfamily (Wang, Wei…